Greehey CCRI Seminar Series Spring ’22: Jason Yustein, Baylor College of Medicine

Event Date & Time

April 22, 2022 at 11:00 AM CDT

Location

https://zoom.us/j/91409021393?pwd=YzloQnFvalFtVXE4T0YybWMxZEZsQT09


Event Details:
Presentation Title: “Modeling and Targeting Metastatic Sarcomas”

Greehey CCRI Host:
Gregory Aune, MD, PhD
Alexander Pertsemlidis, PhD

Save to Calendar

Add to Calendar

Share this event

About the Speaker(s)

Yustein
Jason T. Yustein, M.D., Ph.D.
Associate Professor

Due to the relatively inferior long-term patient outcomes, we recognize the need for improving our understanding of pediatric sarcomas, specifically osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma. The laboratory has tremendous interest and experience in merging innovative murine models and patient-derived resources towards garnering molecular insights into sarcoma initiation, development, and metastatic progression and translating these findings towards testing novel therapeutic interventions.

Research in our laboratory is focused on these areas:

Utilizing tissue-specific genetic perturbation to form novel, applicable transgenic mouse models of metastatic osteosarcoma and rhabdomyosarcoma, both conditions that have particularly poor patient outcomes. Such models allow for further understanding of critical genetic and proteomic alterations involved in sarcoma development, progression, and metastasis and can be utilized as preclinical models for therapeutic testing and efficacy.

Use of innovative in vitro, ex vivo, and in vivo models in order to investigate the roles of critical signal transduction mechanisms, such as the Wnt-signaling pathway, in the metastatic and therapeutic resistant conditions.

Investigating the role and the therapeutic potential of the tumor microenvironment, focusing on non-tumor cell contributions and metabolic alterations, towards sarcoma initiation, development, and progression.

We have developed multiple collaborations within Baylor College of Medicine, as well as local, domestic and international institutions to further enhance our studies from a basic science and translational/clinical approach. Also, utilizing the strengths and resources of the Developmental Therapeutics Program at Texas Children’s Cancer Center, we have formed collaborations with multiple pharmaceutical companies to test the efficacy of novel therapeutic agents on pediatric sarcomas.

View Yustein Lab